These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 1790140)

  • 21. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
    Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
    Pendurthi TK; Schlom J; Primus FJ
    J Immunother (1991); 1991 Feb; 10(1):2-12. PubMed ID: 2012797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.
    Itoh K; Hayakawa K; Salmeron MA; Legha SS; Murray JL; Talpaz M; Balch CM; Parkinson DR; Lee K; Zukiwski AA
    Cancer Immunol Immunother; 1991; 33(4):238-46. PubMed ID: 2059968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
    Fox BA; Spiess PJ; Kasid A; Puri R; Mulé JJ; Weber JS; Rosenberg SA
    J Biol Response Mod; 1990 Oct; 9(5):499-511. PubMed ID: 2174966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2.
    Khoo NK; Chan FP; Saarloos MN; Lala PK
    Clin Exp Metastasis; 1992 Jul; 10(4):239-52. PubMed ID: 1617832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody.
    Kikuchi T; Watanabe M; Ohno T
    Jpn J Cancer Res; 1991 Mar; 82(3):339-45. PubMed ID: 1827092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN; Khoo NK; Lala PK
    Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients.
    Logan TF; Gooding WE; Whiteside TL; Ernstoff MS; Kaplan SS; Miketic L; Vlock DR; Tompkins C; Wood DL; Nadler PI; Kirkwood JM
    J Immunother; 1997 Sep; 20(5):387-98. PubMed ID: 9336746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral blood and tumor infiltrating lymphocytes in non-small cell lung cancer: analysis at the population and clonal level.
    Viale M; Ferrini S; Serrano S; Serrano D; Ardizzoni A; Nicolin A
    Tumori; 1990 Oct; 76(5):488-94. PubMed ID: 2175060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive immunotherapy of intracerebral metastases in mice.
    McCutcheon IE; Baranco RA; Katz DA; Saris SC
    J Neurosurg; 1990 Jan; 72(1):102-9. PubMed ID: 2294169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
    Fukuta K; Sone S; Kitahara M; Okada M; Ogura T
    Jpn J Cancer Res; 1989 Jun; 80(6):562-7. PubMed ID: 2503476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.
    Mansfield PF; Rosenblum MG; Murray JL; Itoh K
    Cancer Immunol Immunother; 1991; 33(4):247-54. PubMed ID: 1829394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model.
    Elzaouk L; Moelling K; Pavlovic J
    Exp Dermatol; 2006 Nov; 15(11):865-74. PubMed ID: 17002683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
    Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K
    Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.